menu
    • menu
    [{"orgOrder":0,"company":"CURIUM US LLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"177Lu-PSMA-I&T","moa":"PSMA","graph1":"Oncology","graph2":"Phase III","graph3":"CURIUM US LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CURIUM US LLC \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CURIUM US LLC \/ Not Applicable"},{"orgOrder":0,"company":"CURIUM US LLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lu-177-PSMA-I&T","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"CURIUM US LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"CURIUM US LLC \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CURIUM US LLC \/ Not Applicable"},{"orgOrder":0,"company":"CURIUM US LLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Dotatate Lutenium Lu-177","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"CURIUM US LLC","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"CURIUM US LLC \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"CURIUM US LLC \/ Not Applicable"},{"orgOrder":0,"company":"CURIUM US LLC","sponsor":"PDRadiopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"177Lu-PSMA-I&T","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"CURIUM US LLC","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"CURIUM US LLC \/ CURIUM US LLC","highestDevelopmentStatusID":"14","companyTruncated":"CURIUM US LLC \/ CURIUM US LLC"}]

    Find Clinical Drug Pipeline Developments & Deals by CURIUM US LLC

    Menu

    CURIUM US LLC

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CURIUM US LLC

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            CURIUM US LLC

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177Lu-PSMA-I&T

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : PDRadiopharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Curium Partners with PeptiDream for Prostate Cancer Theranostics in Japan

                            Details : Under the terms of the partnership, Curium and PDRadiopharma will jointly collaborate on clinical development activities of 177Lu-PSMA-I&T and 64Cu-PSMA-I&T in Japan.

                            Brand Name : 177Lu-PSMA-I&T

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 01, 2024

                            Lead Product(s) : 177Lu-PSMA-I&T

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : PDRadiopharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CURIUM US LLC

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            CURIUM US LLC

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dotatate Lutenium Lu-177

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Curium Submits New Drug Application for Lutetium Lu 177 Dotatate Injection

                            Details : Lutetium Lu 177 Dotatate is an IV, SSRT2 inhibitor, radiolabeled somatostatin analog indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 09, 2024

                            Lead Product(s) : Dotatate Lutenium Lu-177

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            CURIUM US LLC

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            CURIUM US LLC

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lu-177-PSMA-I&T

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Curium Confirms No Supply Challenges of 177Lu-PSMA-I&T for ECLIPSE Trial

                            Details : No supply challenges of Lu-177-PSMA for the Phase 3 ECLIPSE clinical trial (NCT05204927), evaluating Lutetium 177LuPSMA-I&T treatment compared to the standard of care hormone therapy in men with metastatic Castration-Resistant Prostate Cancer.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 12, 2022

                            Lead Product(s) : Lu-177-PSMA-I&T

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            CURIUM US LLC

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            CURIUM US LLC

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177Lu-PSMA-I&T

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Curium’s Phase 3 ECLIPSE Trial Starts Enrolling Patients

                            Details : ECLIPSE is a Phase 3, multi-center, open-label, randomized clinical trial comparing the safety and efficacy of 177Lu-PSMA-I&T versus standard of care hormone therapy in patients with metastatic castration-resistant prostate cancer.

                            Brand Name : 177Lu-PSMA-I&T

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 03, 2022

                            Lead Product(s) : 177Lu-PSMA-I&T

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth